<DOC>
	<DOCNO>NCT01777243</DOCNO>
	<brief_summary>The study conduct two part . The first ( Part A ) open label single dose escalation part begin propose start dose level GSK2398852 5 milligram ( mg ) [ approximately equivalent 0.1 mg/kilogram ( kg ) ] . The next escalation dose level propose 1 mg/kg , 3 mg/kg , 10 mg/kg 30 mg/kg . GSK2315698 administer variable dos concentration serum amyloid P component monoclonal antibody ( SAP mAb ) fall 100 nanogram/millilitre ( ng/mL ) . Decisions next dose level make follow safety review prior subject ' data ; dose level may change ( increase lower ) dose level may repeat depend observe safety Part A extension study may perform . In addition , pharmacokinetics GSK2315698 ( SAP depleter ) GSK2398852 ( anti-SAP mAb ) , circulate SAP concentration assess . Dose escalation Part A continue high well tolerate dose high allowable dose . Subjects closely monitored undergo Equilibrium contrast Magnetic Resonance Imaging ( EqMRI ) include organ volume , Elastography Liver Biopsy require . Part B randomize partially blind part principal objective assess dose response GSK2398852 detail . Subjects assign one approximately 5 dose group Part A . The precise selection number subject dose level inform result Part A .</brief_summary>
	<brief_title>A Study Evaluate Safety GSK2398852 When Co-administered With GSK2315698 Patients With Systemic Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Subject medically diagnose systemic amyloidosis fall one patient group ( small moderate amyloid load involve spleen Part A ; moderate large amyloid load involve spleen ( moderate/large extent ) Part A ( follow agreement external safety committee ) ; moderate large amyloid load involve spleen liver ( spleen involve moderate/large extent ) Part A extension ( require ) ; moderate large amyloid load involve spleen ( liver subset subject ) Part B ) . Alanine aminotransferase ( ALT ) &lt; 3x upper limit normal ( ULN ) bilirubin &lt; 1.5x ULN ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Male female 18 70 year age inclusive , time signing informed consent . Subject ambulant capable attend study visit schedule . Capable give write informed consent , include compliance requirement restriction list consent form . A female subject eligible participate nonchildbearing potential ; female hormone replacement therapy ( HRT ) whose menopausal status doubt require use one approve contraception method . Male subject female partner childbearing potential must agree use one approve contraception method . Smokers ( &lt; 10 /day ) permit must willing abstain duration residential study session A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen The subject participate clinical trial receive investigational therapeutic product ( unlicensed ) within follow time period prior first dose day current study : 3 month , 5 halflives twice duration biological effect investigational product ( whichever longer ) . This timeframe apply short term administration GSK2315698 study CPH114527 . Pregnant female determine positive serum urine human chorionic gonadotropin ( hCG ) test screen prior dosing . Lactating female . Estimated glomerular filtration rate ( GFR ) &lt; 30 milliliter ( mL ) /minute ( min ) [ &lt; 60 mL/min first 4 subject enrol ] Evidence active urinary sediment microscopy evidence presence red cell cast Decompensated cardiac failure recent history syncope associate cardiac disease . In subject clinical suspicion cardiac amyloid , echocardiogram consistent significant cardiac amyloid , whether symptomatic . Clinically significant anaemia hemoglobin ( Hb ) &lt; 9 gram ( g ) /deciliter ( dL ) . Use prohibit medication . Poor unsuitable venous access . Subjects QT interval correct use Fridericia 's formula ( QTcF ) &gt; 480 m electrocardiogram ( ECG ) abnormality , opinion investigator clinically significant may increase safety risk . Uncontrolled hypertension systolic blood pressure ( BP ) &gt; 170 mmHg /or diastolic &gt; 100 mmHg Presence comorbid condition ( e.g . severe unstable coronary artery disease ; moderatesevere chronic obstructive pulmonary disease ) opinion investigator would increase potential risk subject . Subjects active vasculitis Exclusions Equilibrium contrast Magnetic Resonance Imaging ( EqMRI ) scan [ Contraindications Magnetic Resonance Imaging ( MRI ) scan include , limited : Intracranial aneurism clip ( except Sugita ) ; History intraorbital metal fragment remove MD ( confirm orbital XRay ) ; Pacemakers nonMR compatible heart valve ; Inner ear implant ; History claustrophobia ; estimate GFR &lt; 30 mL/min ( gadolinium exclusion ) ] Subjects dementia diagnosis cerebral amyloid angiopathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>systemic amyloidosis</keyword>
	<keyword>safety</keyword>
	<keyword>dose escalation</keyword>
	<keyword>Carboxy Pyrrolidine Hexanoyl Pyrrolidine Carboxylate ( CPHPC )</keyword>
	<keyword>biomarker</keyword>
	<keyword>GSK2315698</keyword>
	<keyword>GSK2398852</keyword>
	<keyword>SAP</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>co-administration</keyword>
	<keyword>intravenous</keyword>
</DOC>